65,437 trials
Vulvar and Vaginal Atrophy
Primary: The Primary Efficacy Endpoint — 49; 59; 52; 63 participants — p=<0.0001
Urinary Tract Infections · Acute Pyelonephritis
Primary: Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population — 207; 83 Participants — p=0.0088
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Primary: Number of Adverse Events in Participants — 6; 64 Participants
Aortic Valve Disease · Aortic Valve Disorder
Primary: Freedom From Surgical Valve Replacement or Transcatheter Valve-in-Valve Implantation — 95.8 percentage of participants
Healthy
Primary: Area Under the Concentration-time Curve of 3 Different Formulations of Nintedanib (MR1, MR2 and Ofev®) in Plasma Over the Time Interval From 0 Extrapolated to Infinity…
Glioblastoma
Primary: Objective Response Rate (Complete Response and Partial Response) — 0; 1 Participants
Hearing Loss · Hearing Loss, Sensorineural · Hearing Loss, Bilateral
Primary: Diapix Conversation Task: Average Time Per Correctly Identified Difference — 2.47; 2.45 Minute
Prematurity; Extreme
Primary: Cerebral Regional Oxygen Saturation (cRSO2) — 73.4 percent rcSO2
Respiratory Distress Syndrome
Primary: Intubation and Instillation of Liquid Surfactant — 69; 120 Participants
Adhesive Capsulitis
Primary: Comparison of Range of Motion of the Shoulder — 61; 49; 80; 64 degrees
Healthy Adults · Stress
Primary: Magnitude of Change in High Frequency Heart Rate Variability — 399; 421 milliseconds^2
Cardiac Catheterization · Blood Pressure · Heart Ventricles
Primary: Agreement Between SHAPE and Pressure Catheter Measurements — -0.8; -0.8 Correlation coefficient value
Contiguous Stage II Adult Diffuse Large Cell Lymphoma · Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma · Stage I Adult Diffuse Large Cell Lymphoma
Primary: Recommended Phase II Dose (Phase I) — 20; 56 mg/m^2
Metastatic Soft Tissue Sarcoma · Locally Advanced Soft Tissue Sarcoma · Unresectable Soft Tissue Sarcoma
Primary: Progression-free Survival — 83; 170 Days
Healthy
Primary: Local AEs — 500; 344; 186; 189 injections